Table 4.
Resting heart rate changes with bromocriptine‐QR vs placebo stratified by baseline resting heart rate and baseline haemoglobin A1c
| Baseline RHR groups stratified by baseline HbA1c | Bromocriptine‐QR (B‐QR) | Placebo (P) |
Between‐treatment group difference in RHR change Week 0‐24 (P‐value) |
||||
|---|---|---|---|---|---|---|---|
| RHR at baseline |
RHR change Week 0‐24 |
RHR at baseline |
RHR change Week 0‐24 |
||||
| Baseline RHR <70 BPM | |||||||
| HbA1c ≤7 (N = 295 B‐QR, 177 P) | 60 ± 0.4 | 1.7 ± 0.4*** | 60 ± 0.4 | 1.7 ± 0.5*** | 0.04 ± 0.7 (P = .95) | ||
| HbA1c >7 (N = 103 B‐QR, 66 P) | 61 ± 0.6 | 1.4 ± 0.8 | 60 ± 0.6 | 2.8 ± 0.9** | −1.4 ± 1.2 (P = .25) | ||
| HbA1c ≥7.5 (N = 60 B‐QR, 41 P) | 60 ± 0.8 | 1.1 ± 1.1 | 61 ± 0.8 | 2.0 ± 1.2 | −0.9 ± 1.7 (P = .6) | ||
| Baseline RHR ≥70 BPM | |||||||
| HbA1c ≤7 (N = 148 B‐QR, 87 P) | 78 ± 0.6 | −5.2 ± 0.8*** | 77 ± 0.7 | −2.5 ± 0.9** | −2.7 ± 1.2 (P = .03) | ||
| HbA1c >7 (N = 95 B‐QR, 42 P) | 79 ± 0.8 | −4.3 ± 0.9*** | 77 ± 0.9 | 0.7 ± 1.1 | −5.0 ± 1.6 (P = .002) | ||
| HbA1c ≥7.5 (N = 61 B‐QR, 31 P) | 79 ± 1.0 | −4.5 ± 1.2*** | 77 ± 1.2 | 1.6 ± 1.2 | −6.1 ± 1.9 (P = .002) | ||
| Baseline RHR ≥80 BPM | |||||||
| HbA1c ≤7 (N = 47 B‐QR, 29 P) | 86 ± 0.0.9 | −8.6 ± 1.6*** | 86 ± 0.7 | −4.1 ± 1.8* | −4.5 ± 2.4 (P = .07) | ||
| HbA1c >7 (N = 38 B‐QR, 10 P) | 87 ± 1.1 | −6.5 ± 1.5*** | 85 ± 2.2 | 1.3 ± 1.7 | −7.8 ± 3.1 (P = .015) | ||
| HbA1c ≥7.5 (N = 24 B‐QR, 9 P) | 86 ± 1.4 | −8.1 ± 1.9*** | 85 ± 2.4 | 1.8 ± 1.9 | −9.9 ± 3.3 (P = .005) | ||
Data shown as mean ± standard error of mean.
Abbreviations: HbA1c, haemoglobin A1c; RHR, resting heart rate.
*
P < .05 for within‐treatment group change in RHR.
**
P ≤ .01 for within‐treatment group change in RHR.
***
P ≤ .001 for within‐treatment group change in RHR.